Form 13-F position report

SAB BIOTHERAPEUTICS INC

Reported by STATE STREET CORPORATION

SABS CUSIP 78397T202 Manager CIK 0000093751

Reported 737,138 shares, up 206,307 (38.9%) from the prior quarter.

Reported value 12.9%; share count 38.9% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 737,138 Quarter-end amount reported
Reported value $2,336,727 Fair value at quarter end
Consecutive quarters held 4 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 96000
2022-03-31 159000
2022-06-30 118000
2022-09-30 57000
2022-12-31 47924
2023-03-31 35746
2023-06-30 67430
2023-09-30 51182
2023-12-31 55853
2024-03-31 0
2025-12-31 49076
2026-03-31 284305
2026-06-30 2070241
2026-09-30 2336727

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for SAB BIOTHERAPEUTICS INC held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 737,138 +206,307 (38.9%) < 0.01% $2,336,727 2026-11-12
Q2 2026 Added 530,831 +456,600 (615.1%) < 0.01% $2,070,241 2026-08-07
Q1 2026 Added 74,231 +61,109 (465.7%) < 0.01% $284,305 2026-05-15
Q4 2025 New 13,122 +13,122 (0.0%) < 0.01% $49,076 2026-02-13
Q1 2024 Reduced 0 -81,241 (-100.0%) 0 $0 2024-05-15
Q4 2023 Unchanged 81,241 0 (0.0%) < 0.01% $55,853 2024-02-14
Q3 2023 Unchanged 81,241 0 (0.0%) < 0.01% $51,182 2023-11-14
Q2 2023 Unchanged 81,241 0 (0.0%) < 0.01% $67,430 2023-08-14
Q1 2023 Unchanged 81,241 0 (0.0%) < 0.01% $35,746 2023-05-15
Q4 2022 Unchanged 81,241 0 (0.0%) < 0.01% $47,924 2023-02-14
Q3 2022 Unchanged 81,241 0 (0.0%) < 0.01% $57,000 2022-11-15
Q2 2022 Added 81,241 +38,900 (91.9%) < 0.01% $118,000 2022-08-15
Q1 2022 Added 42,341 +30,041 (244.2%) < 0.01% $159,000 2022-05-16
Q4 2021 New 12,300 +12,300 (0.0%) < 0.01% $96,000 2022-02-14

Who else reported the position

106 managers reported SAB BIOTHERAPEUTICS INC for Q3 2026.

Managers reporting SAB BIOTHERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Caligan Partners LP Added 8,736,898 +769,691 1.69% $27,695,967 3 qtrs
Vivo Capital LLC Reduced 6,915,011 -384,898 2.41% $21,920,585 5 qtrs
PERCEPTIVE ADVISORS LLC Unchanged 6,627,501 0 0.37% $21,009,178 4 qtrs
ADAGE CAPITAL PARTNERS GP L L C Unchanged 6,405,553 0 0.03% $20,305,603 3 qtrs
RA CAPITAL MANAGEMENT L P Unchanged 4,401,500 0 0.14% $13,952,755 5 qtrs
Balyasny Asset Management LLC Unchanged 3,760,439 0 0.01% $11,920,592 4 qtrs
BlackRock Inc Added 3,572,073 +506,057 < 0.01% $11,323,472 9 qtrs
MILLENNIUM MANAGEMENT LLC Added 3,453,920 +704,833 < 0.01% $10,948,926 4 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 3,088,536 +115,607 < 0.01% $9,790,659 3 qtrs
COMMODORE CAPITAL LP Unchanged 2,870,000 0 0.7% $9,097,900 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 12, 2026
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
229,803
Shared
0
None
507,335

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.